At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 21, 2026 at 11:23 ET
Revolution Medicines announced that detailed results from its Phase 3 RASolute 302 trial of daraxonrasib in metastatic pancreatic cancer will be presented at ASCO 2026, following previously reported unprecedented overall survival benefit. The drug met all primary and key secondary endpoints, including statistically significant improvements in progression-free and overall survival versus chemotherapy.
- Daraxonrasib demonstrated statistically significant and clinically meaningful improvement in both PFS and OS vs standard chemotherapy in previously treated metastatic PDAC.
- Results from the Phase 3 RASolute 302 trial will be presented in a Plenary Session at ASCO 2026, a high-profile venue indicating clinical importance.
- FDA has granted Breakthrough Therapy and Orphan Drug Designations for daraxonrasib; it is also part of the FDA Commissioner’s National Priority Voucher program.
- The trial included patients with various RAS mutations (G12D, G12V, G12R) and RAS wild-type, broadening potential applicability.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access